说明:双击或选中下面任意单词,将显示该词的音标、读音、翻译等;选中中文或多个词,将显示翻译。
您的位置:首页 -> 句库 -> 凝血酶激活的纤溶抑制物
1.
Studies on the Thrombin Activatable Fibrinolysis Inhibitor of Coronary Atherosclerotic Heart Disease;
冠心病患者凝血酶激活的纤溶抑制物研究
2.
Relationship between Thrombin Activated Fibrinolysis Inhibitor in Plasma and Vascular Complication in Type 2 Diabetes;
血浆凝血酶激活的纤溶抑制物与2型糖尿病血管并发症的关系
3.
Analysis of the Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Fibrinogen in Patients with Coronary Atherosclerotic Heart Disease
冠心病患者凝血酶激活的纤溶抑制物与纤维蛋白原关系分析
4.
Study of the Relativity between Thrombin-activatable Fibrinolysis Inhibtor and Stroke
血浆凝血酶激活的纤溶抑制物与脑卒中的相关性研究
5.
The Relationship between Thrombin-Activatable Fibrinolysis Inhibitor and Risk of Stroke
血浆凝血酶激活的纤溶抑制物与脑卒中的相关性
6.
The clinical study of plasma thrombin activatable fibrinolysis inhibitor in the patients with stroke
脑卒中患者血浆凝血酶激活的纤溶抑制物的临床研究
7.
A Study of Relation between Thrombin Activatable Fi Brinolysis Inhibition and Coronary Heart Disease.;
凝血酶激活的纤溶抑制物与冠心病的相关性研究
8.
Genetic polymorphism of thrombin-activatable fibrinolysis inhibitor(TAFI) associated with type 2 diabetes mellitus
凝血酶激活的纤溶抑制物编码区基因多态性与2型糖尿病的关系
9.
Study on the Association of the Gene Polymorphism of Thrombin Activatable Fibrinolysis Inhibitor with Coronary Atherosclerotic Heart Disease;
冠心病患者凝血酶激活的纤溶抑制物及其编码区基因CPB2多态性的研究
10.
Study on the the Association of Genetic Variations in Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Encoding Region and the Risk of Type 2 Diabetes Mellitus
凝血酶激活的纤溶抑制物编码区基因CPB2多态性与2型糖尿病关系的研究
11.
Effects of Thrombin-activable Fibrinolysis Inhibitor and Hirudin on Fibrinolysis;
凝血酶激活的纤溶抑制剂与水蛭素对纤溶的影响
12.
Study on the Levels of Thrombin Activable Fibrinolysis Inhibitor Active(TAFIa) in the Patients with Hemophilia
血友病患者凝血酶激活的纤维蛋白溶解抑制物活性(TAFIa)的检测及其临床意义
13.
Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;
慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
14.
Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases
纤溶酶原激活物抑制剂-1与心血管疾病
15.
Activity of plasma tissue plasminogen activator and plasminogen activator inhibitor in patients with hypertensive disorder complicating pregnancy
妊娠期高血压疾病患者血浆组织型纤溶酶原激活物及其抑制物的活性变化
16.
The relation of plasma plasminogen activator inhibitor activity and coronary heart disease
纤溶酶原激活抑制物活性与冠心病发病关系
17.
The Varity and Mechnisim of the Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes with Hypertriglyceridemia;
伴高甘油三酯血症的2型糖尿病纤溶酶原激活物抑制物-1水平变化及机制探讨
18.
The Role of the Plasminogen Activator Inhibitor-1 in the Pathogenesis of Hepatic Fibrosis;
纤溶酶原激活物抑制剂-1在肝纤维化发生中的作用